AASTOCKS Financial News

HSI¹	25,116.53	-177.50	243.63B
HSCEI¹	8,456.92	-47.89	82.60B

Back Zoom + Zoom - Block Traded

Novo Nordisk (NVO.US) Prices High-Dose Wegovy at USD399 per Month, Below Eli Lilly (LLY.US) Zepbound
2026-04-07 21:17:11
Novo Nordisk (NVO.US) said it has priced its newly launched high-dose weight-loss injection Wegovy at USD399 per month for self-paying patients, lower than most doses of rival Eli Lilly (LLY.US)'s Zepbound.

Novo Nordisk noted that the high-dose Wegovy will be available starting Tuesday. The price is about 40% lower than the highest three doses of Zepbound charged by Eli Lilly to self-paying patients.

(me/t)~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

(1) HK Indices are real time

Home|RT Quote|Market|News|Indices
Feedback

View: Mobile|Desktop
Lang: 繁|简|EN

Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.